Nearly half (44%) of recently surveyed pharmaceutical, biotechnology, and clinical research professionals have already adopted remote patient monitoring (RPM) for decentralized clinical trials (DCTs) or have plans to within the next 12 months.
According to a press release about the survey results announced last week by VivaLNK, the adoption of remote monitoring during trials stems largely from COVID-19, as 65% of respondents noted concerns related to the pandemic as their primary driver for using RPM technology.
Maintaining the integrity of data collected during a trial is a top priority, with 94% of respondents indicating that continuous data capture was somewhat or very important to their trials. While most physiological parameters are of importance to monitor across the board, heart rate and blood pressure were cited as the most important to track for trials, with 69% and 57% citing those, respectively.
While this practice is certainly growing in popularity within clinical trials, patient adherence continues to be a concern to the adoption of RPM, with 69% of respondents noting that as the biggest challenge. In addition to the use of medical grade devices in trials, video conferencing between clinicians and subjects for communication purposes has increased in popularity, with 71% of respondents stating that they utilize this technology in trials.
“COVID-19 has accelerated the demand for [RPM], as evidenced by the rapid adoption we have seen over the past year,” said Jiang Li, CEO of VivaLNK. “We are continuing to see rapid [adaptation of clinical trials] to a decentralized model. The successful technology for such an application needs to have patient-friendly medical sensors in combination with robust data delivery and aggregation.”
Edited by Gary Cramer